Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|1|212-220

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.1, 2015-07, pp. : 212-220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: Is it necessary for all patients?

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 4, 2015-04 ,pp. : 439-444

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic factors for low rectal cancer patients undergoing intersphincteric resection after neoadjuvant chemoradiation

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 8, 2015-06 ,pp. : 1054-1058

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neo‐adjuvant chemoradiation

By  

JOURNAL OF MAGNETIC RESONANCE IMAGING, Vol. 41, Iss. 6, 2015-06 ,pp. : 1646-1653

John Wiley & Sons Inc

Access to resources Recommend Favorite

Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence‐free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4231-4241

John Wiley & Sons Inc

Access to resources Recommend Favorite

Delivery of neoadjuvant chemoradiation for patients with stage II and III rectal cancer is suboptimal

By  

CA: A CANCER JOURNAL FOR CLINICIANS, Vol. 66, Iss. 5, 2016-09 ,pp. : 357-358

John Wiley & Sons Inc

Access to resources Recommend Favorite